Revolution (RVMD) PT Lowered to $59 at Needham

Needham analyst Ami Fadia lowered the price target on Revolution (NASDAQ: RVMD) to $59.00 (from $60.00) while maintaining a Buy rating.

The analyst commented: "4Q24 EPS of -$1.12 was higher than cons of -$0.99 based on higher R&D (-$24.7M vs. cons.). For 2025, mgt provided guidance with net loss of $840-900M. The main update from the earnings was the addition of 2 registrational trials for daraxonrasib in earlier lines of PDAC, including 1L PDAC and adjuvant setting for resectable PDAC, expected to initiate in 2H25. We anticipate the stock should react positively to this news especially the addition of adjuvant setting in PDAC as this increases the TAM for dara (~15 — 20% of newly diagnosed PDAC patients present with resectable tumor). We update our model for the quarter and raise projected expenses for 2025 as per guidance which lowers our PT to $59. Next, we look for additional clinical data for zoldonrasib (RMC-9805) monotherapy in 2Q25 and combination therapy in 2Q/3Q25."

You May Also Be Interested In

• Bicara Therapeutics Inc (BCAX) PT Raised to $39 at BTIG
• Canterbury Park (CPHC) Misses Q2 EPS by 3c
• RideNow Group, Inc. (RDNW) Tops Q2 EPS by 4c